Clindamycin Phosphate Topical Solution Recalled for Defective Container
Contract Pharmaceuticals is recalling Clindamycin Phosphate Topical Solution USP 1% due to defective containers that leak under the cap. The recall affects 11,350 bottles distributed nationwide.
What this means for you
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: This is an FDA Class III recall involving a defective container with slow leakage under the cap. No illnesses or injuries have been reported. Packaging defects without associated harm are classified as Low severity.
Plain-English summary
Contract Pharmaceuticals Limited Canada is recalling Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottles (NDC 71428-003-60). The recalled product is Lot 118920 with an expiration date of January 2024.
The containers have been found to leak slowly under the cap. This defect may compromise the integrity and stability of the medication.
The recalled product was distributed nationwide in the United States. Approximately 11,350 bottles are affected.
Healthcare providers and consumers in possession of this medication should discontinue use. Those with questions should contact their healthcare provider or pharmacist.
The recalled product
- Product
- Clindamycin Phosphate Topical Solution USP, 1%, 60 mL bottle, Rx only, Manufactured by: Contract Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, Manufactured for: Glasshouse Pharmaceuticals Limited Canada, Mississauga, Ontario, Canada, NDC# 71428-003-60
- Manufacturer
- Contract Pharmaceuticals Limited Canada
- Category
- Drug — Topical Solution
- Hazard
- defective-container
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 118920
- exp. January 2024.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27
- LowPrimidone Tablets Recalled for Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27